(Nasdaq: CVKD) Puts Today's Bell In The Rearview (Low Float Idea With Breaking News)

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) takes the spotlight at the top of today's watchlist

*Sponsored (Nasdaq: CVKD) Puts Today's Bell In The Rearview (Low Float Idea With Breaking News) June 12th Dear Reader, Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) takes the spotlight at the top of today's watchlist. Now, on the other side of the bell, it's time to take a closer look. First off, check out the breaking news: Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients From the article: "Despite decades of use, warfarin has significant limitations – especially in complex patients with LVADs," said Quang X. Pham, Chairman and CEO of Cadrenal Therapeutics. "This research reinforces our conviction that tecarfarin has the potential to transform anticoagulation management for this high-risk population who currently has no alternative options." With this news, it's important to take note of CVKD's low float of fewer than 2Mn shares. Additionally, a pair of analyst targets (more info below) suggest strong upside potential from current levels. Review my initial report below for more details and consider (Nasdaq: CVKD) for your radar. ----- Imagine a world where patients with advanced heart failure and rare cardiovascular conditions finally have a safer, more effective option for chronic blood clot prevention. A late-stage biopharmaceutical company, recently recognized with FDA orphan drug designations, is advancing a novel oral anticoagulant—engineered to overcome the limitations of traditional therapies by sidestepping common drug interactions and kidney-related complications. With pivotal clinical trials on the horizon and strong partnerships with leading device manufacturers, this organization is poised to transform care for underserved populations.  The future of cardiovascular medicine is shifting, and this team is at the center of that change. Now, mix in a low float of fewer than 2Mn shares and a pair of analyst targets suggesting SIGNIFICANT upside potential, and there's no doubt why this Nasdaq profile just rocketed up my watchlist. Drop what you're doing and consider this under-the-radar idea for your radar: *Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)* Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with cardiovascular disease. Cadrenal’s lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that addresses unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. And based on several potential breakout catalysts, (Nasdaq: CVKD) has found its way to the top of my watchlist. Check them out: #1. A Low Float Could Create An Environment Of Heightened Volatility Potential. #2. A $45 Analyst Target Suggests Triple-Digit Potential Upside From Current Levels. #3. Another Analyst Reiterates A $30 Target For CVKD. #4. A Key Collaboration Agreement Strengthens Access To Clinical Trial Sites. #5. Manufacturing And Supply Chain Milestones For Tecafarin Mark Important Progress. But more on those in a second... Company Breakdown: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, an investigational anticoagulant designed as a superior and safer Vitamin K antagonist (VKA) for patients with implanted cardiac devices or rare cardiovascular conditions. The company strives to improve patient outcomes and reduce major adverse events among these populations, who currently lack any approved chronic anticoagulation options besides warfarin—a medication known for its serious side effects and complex management requirements. Through its innovative approach, Cadrenal aims to alleviate some of the most significant challenges faced by patients and healthcare providers who rely on warfarin. Cadrenal’s Phase 3-ready drug candidate, tecarfarin, represents a novel VKA anticoagulant supported by extensive data suggesting its potential to be superior to warfarin, with the possibility of fewer adverse events such as strokes, heart attacks, bleeding, and death. Tecarfarin has received orphan drug designation for heart failure patients with left ventricular assist devices (LVADs), as well as both orphan drug and fast track status for end-stage kidney disease (ESKD) patients with atrial fibrillation (Afib). The company is actively pursuing pivotal clinical trials and exploring clinical and commercial partnership opp's. Cadrenal also plans to investigate tecarfarin in patients with mechanical heart valves who experience anticoagulation difficulties due to genetic warfarin resistance, polypharmacy, or kidney impairment. Tecarfarin is metabolized through a different pathway than warfarin, and data indicate that its efficacy remains unaffected by common drug-drug interactions or kidney impairment—challenges that are prevalent among these patient populations. Phase 2/3 clinical trials have demonstrated that tecarfarin may offer greater stability and increased time in therapeutic range, which is inversely correlated with major adverse events. As the only new VKA blood thinner in development specifically for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions, Cadrenal is boldly challenging the status quo, seeking to innovate a new anticoagulant that delivers better care to underserved patients. Tecarfarin’s Metabolic Advantage Tecarfarin is metabolized via an alternate pathway that is abundant and essentially insaturable, thereby avoiding the bottleneck in the CYP450 pathway where warfarin is metabolized. Tecarfarin Clinical Development Pipeline Grab Sources Here: CVKD Website. ----- And as I mentioned earlier, (Nasdaq: CVKD) has several potential catalysts to consider immediately. Check them out: #1. CVKD Potential Catalyst - A Low Float Could Create An Environment Of Heightened Volatility Potential. According to info from the Yahoo Finance website, CKVD has very low float. The website reports this profile to have roughly 1.39Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. If positive company news appears in the midway part of 2025, could it provide a breakout spark? ----- #2. CVKD Potential Catalyst - A $45 Analyst Target Suggests Triple-Digit Potential Upside From Current Levels. Last month, Noble Capital Markets analyst, Robert LeBoyer, provided CVKD with a $45 price target. From Wednesday's 4:00PM EST closing valuation, that target provides CVKD with a potential upside of 200%! Details from the report: Conclusion. We view tecarfarin’s mechanism of action as an improvement over warfarin, the drug currently used in indications such as LVAD or ESKD with AFIB. The guidance from the FDA and agreement with Abbott for tecarfarin development were important steps toward the start of a pivotal clinical trial. We reiterate our Outperform rating and $45 price target. ----- #3. CVKD Potential Catalyst - Another Analyst Reiterates A $30 Target For CVKD. Another analyst, David Bautz of Zacks Small-Cap Research, recently reiterated a $30 target for CVKD. From its 4:00PM EST close on Wednesday, that targets suggests 100% potential upside for CVKD. Report highlights: We look forward to additional updates from the company regarding the upcoming Phase 3 trial of tecarfarin in LVAD patients. Having Abbott as a partner for the Phase 3 trial is a tremendous opp. for the company as Abbott has extensive experience working with LVAD patients and conducting successful trials with that population. With no changes to our model our valuation remains at $30 per share. ----- #4. CVKD Potential Catalyst - A Key Collaboration Agreement Strengthens Access To Clinical Trial Sites. Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3™ LVAD patients PONTE VEDRA, Fla., March 04, 2025--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, with the late-stage asset tecarfarin, a new oral Vitamin K antagonist (VKA), today announced the signing of a Collaboration Agreement with Abbott (NYSE: ABT) to support Cadrenal’s pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial. Under the terms of the Collaboration and Data Sharing Agreement, Abbott will support Cadrenal on the planning and execution of the TECH-LVAD trial to evaluate the efficacy and safety of tecarfarin in patients with LVADs. Under the Agreement, Abbott will share insights from recent HeartMate 3™ trials and will support Cadrenal with: trial design, site identification, trial awareness, and HeartMate 3™ expertise. "We are pleased to have the support of Abbott, a global healthcare leader, which further validates the advancement into late-stage clinical development of tecarfarin. This partnership strengthens our access to key clinical trial sites and enhances patient enrollment efforts," said Quang X. Pham, Chief Executive Officer, Cadrenal Therapeutics, Inc. "Together, we have a unique opp. to evaluate tecarfarin in combination with the HeartMate 3™ LVAD, advancing our commitment to bringing forward the first innovation in vitamin K-targeted anticoagulation in over 70 years." ... Read the full article here. ----- #5. CVKD Potential Catalyst - Manufacturing And Supply Chain Milestones For Tecafarin Mark Important Progress. Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness PONTE VEDRA, Fla., May 15, 2025--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced manufacturing and supply chain milestones for its lead drug candidate, tecarfarin, a novel oral vitamin K antagonist (VKA) anticoagulant that is designed to address unmet needs in anticoagulation therapy. Cadrenal completed the technical transfer and manufacturing of its tecarfarin drug substance in accordance with current good manufacturing practices (cGMP) earlier this year at a U.S. site of a leading global Contract Development and Manufacturing Organization (CDMO). Manufacturing of the tecarfarin drug product candidate is currently underway. "We are pleased with the important progress we have made with the supply chain and cGMP manufacturing process for tecafarin," said Quang X. Pham, Chairman & CEO. "This is a key milestone as we support our clinical development strategy and tecarfarin’s potential to provide clinical benefits for patients with cardiovascular disease who require chronic VKA anticoagulation." Read the full article here. ----- (Nasdaq: CVKD) Recap - 5 Potential Breakout Catalysts Lead The Way #1. A Low Float Could Create An Environment Of Heightened Volatility Potential. #2. A $45 Analyst Target Suggests Triple-Digit Potential Upside From Current Levels. #3. Another Analyst Reiterates A $30 Target For CVKD. #4. A Key Collaboration Agreement Strengthens Access To Clinical Trial Sites. #5. Manufacturing And Supply Chain Milestones For Tecafarin Mark Important Progress. ----- Coverage is officially initiated on Cadrenal Therapeutics, Inc. (Nasdaq: CVKD). I'll be back to you with updates when necessary. Keep your eyes peeled. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

Fierce | 4834 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice